Orchid Pharma Limited’s Board of Directors has approved the issuance and allotment of 4,45,86,052 fully paid-up equity shares of Rs. 10 each. These shares are allocated to the eligible shareholders of Dhanuka Laboratories Limited as part of an amalgamation scheme. The allotment will increase the company’s paid-up share capital to Rs. 59,88,52,000, comprising 5,98,85,200 shares. These new shares are proposed to be listed on both BSE and NSE.
Orchid Pharma Approves Share Allotment for Amalgamation
At a Board of Directors meeting held on August 01, 2026, Orchid Pharma Limited announced the approval for the issuance and allotment of 4,45,86,052 equity shares. Each share has a face value of Rs. 10 and is fully paid up. This significant share issuance is a part of the approved scheme of Amalgamation with Dhanuka Laboratories Limited. The shares are being allotted to the eligible shareholders of Dhanuka Laboratories Limited, with the record date set for July 23, 2026.
Impact on Share Capital
Following this allotment and the cancellation of cross-holdings in Dhanuka Laboratories Limited, Orchid Pharma’s paid-up share capital will stand at Rs. 59,88,52,000. This amount is divided into 5,98,85,200 equity shares, each with a face value of Rs. 10. The newly issued shares are intended to be listed and traded on both the BSE Limited and the National Stock Exchange of India Limited. These shares will rank pari-passu with the existing equity shares of Orchid Pharma.
Scheme Details
This announcement follows previous intimations made on July 10, 2026, and July 28, 2026, regarding the scheme becoming effective from July 10, 2026. The detailed information as required under Regulation 30 of SEBI Listing Regulations is provided as an annexure to this disclosure.
Source: BSE
